Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P61278 (somatostatin)
 22,083 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The present study was aimed at localizing gamma-aminobutyric acid (GABA) and its enzyme of synthesis, glutamic acid decarboxylase (GAD), in the mouse pancreas by immunocytochemical methods. The influence of GABA on hormone release was also studied with normal mouse and rat islets and the isolated perfused rat pancreas. Particular attention was paid to glucagon release to test a recent hypothesis suggesting that GABA mediates the still unexplained glucose-induced inhibition of glucagon release. GABA and GAD were identified only in islet cells and never in the exocrine tissue. Exogenous GABA, baclofen (agonist of GABAB receptors), muscimol (agonist of GABAA receptors), or bicuculline (antagonist of GABAA receptors) did not affect insulin and somatostatin release by isolated mouse or rat islets. GABA was also without effect on glucose-induced electrical activity in mouse B-cells. Glucagon secretion by mouse islets was only slightly inhibited (approximately 20%) by GABA. Since muscimol had a similar effect, and baclofen was ineffective, the inhibition by GABA probably involves GABAA receptor activation. Bicuculline, however, did not antagonize the inhibitory effects of GABA and muscimol, probably because the antagonist alone also decreased glucagon secretion. In contrast to GABA, low (3 mM) and high (20 mM) concentrations of glucose strongly inhibited (approximately 50-65%) glucagon release; this inhibition was not prevented by bicuculline. Similar results were obtained with the perfused rat pancreas; muscimol slightly inhibited glucagon release under various conditions, and bicuculline did not reverse the strong inhibition produced by 16.7 mM glucose. In conclusion, GABA does not affect insulin and somatostatin secretion, but inhibits A-cells, probably by acting on GABAA receptors. It is unlikely, however, that this small inhibitory effect can account for the inhibition of glucagon release produced by glucose.
 ...
PMID:The influence of gamma-aminobutyric acid on hormone release by the mouse and rat endocrine pancreas. 168 37

Evidence supports the idea that somatostatin (SO) is a neurotransmitter or neuromodulator of primary afferent neurons involved in nociception. Since gamma-aminobutyric acid (GABA), norepinephrine, and morphine alter nociception at the level of the spinal cord, we examined whether these agents could alter the potassium-stimulated release of somatostatin from rat spinal cord slices. Male Sprague-Dawley rats were decapitated and a 2 cm segment of the lumbar spinal cord removed and chopped into 0.5 x 0.5 mm pieces and perfused at 37 degrees C in individual perfusion chambers with a modified Krebs-bicarbonate buffer at a flow rate of 0.5 ml/min. Perfusates were collected at 2 min intervals and assayed for SO using radioimmunoassay. Exposure of spinal cord tissue to 50 mM KCl resulted in a 3-fold increase in release of SO from a basal level of approximately 0.2 to 0.6 pg/mg tissue/min. This evoked release was calcium dependent. Pre-exposure of tissue to GABA at 10(-4) and 10(-5) M significantly inhibited the potassium-stimulated release of SO, but did not alter basal release. The GABA receptor antagonist, bicuculline methiodide, at 10(-5) but not 10(-6) M attenuated the GABA-induced inhibition of somatostatin release. Bicuculline methiodide alone did not significantly alter either basal or stimulated release. Neither baclofen (10(-5) M, 5 x 10(-5) M), norepinephrine (10(-5) M), nor morphine (10(-5) M) had any significant effect on basal or stimulated release of SO from spinal cord tissue.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:gamma-Aminobutyric acid inhibits the potassium-stimulated release of somatostatin from rat spinal cord slices. 196 72

The mechanism of action of somatostatin on the motility of intestine was examined in the entire preparation and the longitudinal muscle attached with Auerbach's plexus (LA) preparation of guinea pig ileum, in relation to the cholinergic neuron and gamma-aminobutyric acid (GABA)ergic neuron. Somatostatin produced a transient potentiation of electrical stimulation-induced twitch contractions followed by an inhibition. The excitatory effect of somatostatin was associated with an increase in the release of [3H]acetylcholine (ACh) from the preparations preloaded with [3H]choline. Bicuculline, a GABAA antagonist, inhibited the somatostatin-induced excitatory effect. Somatostatin inhibited the electrical stimulation-induced twitch contraction and release of [3H]ACh, and the inhibition was greater in the entire preparation than in the LA. Phaclofen, a GABAB antagonist, prevented the inhibitory effects of somatostatin. Somatostatin induced a Ca2+ -dependent, tetrodotoxin-sensitive release of [3H]GABA from the preparations preloaded with [3H]GABA. Therefore somatostatin exerts excitatory and inhibitory effects on the cholinergic neuron due to the stimulation of the GABAergic neuron, and the motility of the intestine is regulated.
 ...
PMID:Putative mechanisms involved in excitatory and inhibitory effects of somatostatin on intestinal motility. 257 73

Localized intracerebral microinjections of GABA, muscimol, picrotoxin and bicuculline were made in the anterior and basal hypothalamus to determine possible sites of action of GABA in the regulation of prolactin and growth hormone (GH) secretion. Studies were carried out in unanesthetized male rats with chronic indwelling atrial cannulae and intracerebral guide cannulae which permitted stress free blood sampling and intrahypothalamic injections, respectively. Preoptic/anterior hypothalamic area. (PO/AHA) injection of muscimol (0.16 nmol) stimulated both prolactin and GH secretion. GABA (1600 nmol) stimulated prolactin. Bicuculline (0.016 and 0.16 nmol) inhibited GH secretion. Medial basal hypothalamic (MBH) injection of muscimol (0.1 and 1.0 nmol) and GABA (1000 nmol) stimulated prolactin but had no effect on GH secretion. Picrotoxin and bicuculline did not stimulate GH. These findings indicate that activation of PO/AHA GABAergic receptors facilitates secretion of GH and prolactin and activation of MBH GABAergic receptors stimulates secretion of prolactin. It is proposed that GABA inhibits somatostatin neurons in the PO/AHA to facilitate GH and inhibits tuberoinfundibular dopamine or GABA neurons in the MBH to stimulate prolactin.
 ...
PMID:Activation of GABA receptors in the hypothalamus stimulates secretion of growth hormone and prolactin. 301 63

The effects of gamma-aminobutyric acid (GABA) on the secretion of insulin, glucagon, and somatostatin were studied in the isolated dog pancreas. Insulin secretion was inhibited in a dose-related fashion for 10 min or more by as little as 1 microM GABA. A prompt but small and transitory rise in somatostatin secretion, lasting only 1 min, occurred at GABA concentrations of 10 and 100 microM, levels that exert inhibitory effects on nervous tissue. Bicuculline, a GABA antagonist, inhibited insulin secretion and did not antagonize GABA-mediated insulin inhibition. The results suggest that GABA in concentrations that are known to exist in islet tissue can influence the secretion of islet hormones.
 ...
PMID:Effects of gamma-aminobutyric acid on insulin, glucagon, and somatostatin release from isolated perfused dog pancreas. 613 11

The interplay of somatostatin, gamma-aminobutyric acid (GABA), and opioid neurons in the regulation of the descending relaxation phase of peristalsis was examined in isolated rat colonic segments. Release of somatostatin, GABA, vasoactive intestinal peptide (VIP), and L-[3H]citrulline [coproduct and index of nitric oxide (NO) production] increased, and release of Met-enkephalin decreased, during descending relaxation. Somatostatin antiserum (1:50) inhibited GABA and L-[3H]citrulline and reversed Met-enkephalin from decrease below to increase above basal level; exogenous somatostatin had the opposite effect. Bicuculline (GABAA antagonist) inhibited L-[3H]citrulline, had no effect on somatostatin, and reversed Met-enkephalin from decrease below to increase above basal level; exogenous GABA had the opposite effect. Naloxone increased GABA and L-[3H]citrulline but had no effect on somatostatin; exogenous Met-enkephalin had the opposite effect. In all instances the changes in L-[3H]citrulline paralleled those previously obtained with VIP. The results are consistent with the operation of a circuit in which somatostatin neurons inhibit the activity of opioid neurons, causing a decrease in Met-enkephalin. The decrease in Met-enkephalin initiated by somatostatin is accentuated by a reciprocal inhibitory pathway linking GABA and opioid neurons. The decrease in Met-enkephalin eliminates the inhibitory influence of opioid neurons on VIP/NO neurons and leads to increase in VIP, NO, and descending relaxation.
 ...
PMID:Interplay of somatostatin, opioid, and GABA neurons in the regulation of the peristaltic reflex. 794 34

GABAA receptors mediate the inhibition of somatostatin release in hypothalamic neurones. To study the possible effect of GABA on somatostatin biosynthesis, somatostatin and preprosomatostatin mRNA levels were evaluated after exposure of hypothalamic neurones to muscimol or bicuculline. Muscimol (50 microM) decreased preprosomatostatin mRNA levels, by 25% after 4 h and 30% after 24 h treatment. Bicuculline (50 microM and 100 microM) increased preprosomatostatin mRNA levels by 1.4 and 1.5 fold after 4 h and by 1.3 and 1.7 fold after 24 h treatment. Somatostatin content was not modified after muscimol or bicuculline exposure. Total DNA content, used to control cellular viability, was not modified under any experimental conditions. Our findings suggest that the GABAergic inhibition of mRNA levels could be a consequence of the GABA inhibition of somatostatin release, thus allowing limited changes in peptide steady-state levels.
 ...
PMID:GABA inhibition of somatostatin gene expression in cultured hypothalamic neurones. 809 10

Somatostatin infusion in rat ventral pallidum (VP) led to the attenuation of locomotor activity (Marazioti, A., Kastellakis, A., Antoniou, K., Papasava, D., Thermos, K., 2005. Somatostatin receptors in the ventral pallidum/substantia innominata modulate rat locomotor activity. Psychopharmacology 181, 319-326). In the present study, we investigated the putative circuitry involved in somatostatin's actions by examining the involvement of GABAergic neurotransmission in locomotor activity subsequent to somatostatin's infusion into the VP. Male Sprague-Dawley rats, 300-350 g, were used for all experiments. Saline or somatostatin (240 ng/0.5 microl/side) in the absence or presence of bicuculline (GABA-A antagonist; 5 mg/kg/ml, i.p.; 120 ng/side nucleus accumbens (NAc)) or phaclofen (GABA-B antagonist; 10 mg/kg/ml, i.p.; 120 ng/side NAc) were infused bilaterally, and the locomotor activity measured for 60 min using a rectangular activity cage. Somatostatin infused in the VP decreased the locomotor activity of the rat in a statistically significant manner. Bicuculline (i.p., and in the NAc) and phaclofen (only i.p.) reversed SRIF's actions, when administered prior to somatostatin's infusion in the VP. The present study provides further information on somatostatin's involvement in the VP-NAc circuitry, and implicates the GABAergic system in somatostatin's actions in the VP.
 ...
PMID:GABA antagonists reverse the somatostatin dependent attenuation of rat locomotor activity. 1941 89